Company / Cash & Equivalents
Gossamer Bio, Inc. Cash & Equivalents History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$37.7M
FY2025
5-year range
$32.1M / $183.4M
FY2021-FY2025
Trend
-18.1%
vs FY2024
Sector context
#191 of 207
Health Care
What the data says
Among 207 Health Care companies, Gossamer Bio, Inc. is in the bottom 8% for cash & equivalents. Cash & Equivalents has fluctuated over the past 8 years, ranging from $32M in FY2023 to $486M in FY2020.
Based on SEC 10-K filings.
$38M in FY2025 with a 5-year CAGR of -40.0%.
Improved from $32M to $38M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -30.4%
- 5-Year CAGR
- -40.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 207This company $37.7M Sector average $669.5M
▼
-94.4% below sector average
Key checks
Key Insights
- 5-year CAGR of -40.0%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 18.1% year-over-year.
- Ranks #191 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -9.62 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $37.7M | -18.1% |
| FY2024 | $46.1M | +43.5% |
| FY2023 | $32.1M | -71.3% |
| FY2022 | $112.0M | -38.9% |
| FY2021 | $183.4M | -62.3% |
| FY2020 | $486.1M | +260.0% |
| FY2019 | $135.0M | +28.3% |
| FY2018 | $105.2M | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026